

DAFTAR PUSTAKA

1. Halim Effendi E. Sindrom Stevens Johnson dan nekrolisis epidermal toksik. Dalam: Menaldi SLS editor. Ilmu Penyakit Kulit dan Kelamin Edisi 7. Jakarta: FK UI; 2017. hlm 199-200.
2. Valeyrie AL CRJ. Epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis). Dalam: Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, Wolff K, editor. Fitzpatrick's dermatology in general medicine. Edisi 8. Amerika Serikat: McGraw-Hill; 2012. hlm 439-448.
3. Maelani N, Sufiawati I, Darmadji HP. The prevalence of stevens johnson syndrome caused by antiretroviral in hospitalized patients at Dr . Hasan Sadikin General Hospital Bandung. Padjadjaran Journal of Dentistry. 2009;21(3):hlm 195–199.
4. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136(7):hlm 1387–1397
5. Yang S-C, Hu S, Zhang S-Z, Huang J, Zhang J, Ji C, et al. The epidemiology of stevens-johnson syndrome and toxic epidermal necrolysis in china. J Immunol Res. 2018;hlm 1–10.
6. Rahayu Amelia, Rina Gustia R. Profil sindrom Stevens Johnson pada pasien rawat inap di RSUP Dr. M. Djamil Padang periode Januari 2010 sampai Desember 2011. Jurnal Kesehatan Andalas. 2014;3(2):hlm 110-113.
7. Mochtar M, Negara WP, Murasmita A. Angka kejadian sindrom Stevens-Johnson dan nekrolisis epidermal toksik RS Dr. Moewardi Surakarta periode Agustus 2011-Agustus 2013. Maj Dermatologi dan Venereol Indones. 2015;42(2):hlm 65–69.
8. Tan S, Tay Y. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;92(1):hlm 62–66.
9. Gravante G, Delogu D, Marianetti M, Trombetta M, Esposito G, Montone A. Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome. Eur Rev Med Pharmacol Sci. 2007;11(2):hlm 119–27.
10. Mahar PD, Wasiak J, Cleland H, Watters D, Paul E, Marsh P, dkk. Mortality and use of the auxiliary score in extensive toxic epidermal necrolysis patients admitted to an adult burns referral centre. Dermatology. 2013;227(2):180–185.

11. Indrastiti R, Novitasari A, Arum C. Faktor prediktor sindrom Stevens-Johnson dan nekrosis epidermal toksik. *Jurnal Kedokteran Muhammadiyah*. 2016;5 (1):hlm 1–6.
12. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. Scortcn: a severity-of-illness score for toxic epidermal necrolysis. *J Invest Dermatol*. 2000;115(2):hlm 149–153.
13. M Barvaliya, J Sanmukhani, T Patel, N Paliwal, H Shah CT. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: A multicentric retrospective study. *JPGM*. 2011;57(2):hlm 115–119.
14. Zajicek R, Pintar D, Broz L, Suca H, Königova R. Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008. *J Eur Acad Dermatology Venereol*. 2012;26(5):hlm 639–643.
15. Thaha MA. Sindrom stevens-jjohnson dan nekrosis epidermal toksis di RSUP MH Palembang periode 2006 - 2008. *Media Med Indones*. 2009;43:hlm 234–239.
16. Rodríguez-martín S, Martín-merino E, Lerma V, Rodríguez-miguel A, González O, González-herrada C, dkk. Incidence of Stevens-Johnson syndrome / toxic epidermal necrolysis among new users of different individual drugs in a european population: a case-population study. *European Journal of Clinical Pharmacology*. 2018.
17. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. *J Invest Dermatol*. 2016;136(7):hlm 1387–1397.
18. Carvalho MR De, Rita M, Garbi C, Novaes AG, Bernarda L, Göttems D. Epidemiological and clinical outcomes analysis in public hospitals*. 2017;92(5):hlm 661–667.
19. Lee HY, Martanto W, Thirumoorthy T. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in Southeast Asia. *Dermatologica Sin*. 2013;31(4):hlm 217–220.
20. Lin Y-C, Sheu J-N, Chung W-H, Pan R-Y, Hung C-J, Cheng J-J, dkk. Vancomycin-induced Stevens-Johnson syndrome in a boy under 2 years old: an early diagnosis by granulysin rapid test. *Front Pediatr*. 2018;6(March):hlm 1–5.
21. Nugraha A, Anwar DJ, Carolia N, Hamzah MS. Stevens Johnson syndrome - toxic epidermal necrolysis overlap disebabkan oleh drug eruption obat anti tuberkulosis. *Medula*. 2017; 7(4):hlm 8–14.
22. Ng CY, Chen CB, Wu MY, Wu J, Yang CH, Hui RCY, dkk. Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies. *J Immunol Res*. 2018.

23. Sarma N. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. *Am J Clin Dermatol*. 2009;10(4):hlm 264–267.
24. Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL. Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort. *J Invest Dermatol*. 2017;137(9):2021–2030.
25. Tamez RL, Tan W V., O'Malley JT, Broder KR, Garzon MC, LaRussa P, dkk. Influenza B virus infection and Stevens–Johnson syndrome. *Pediatr Dermatol*. 2018;35(1): hlm 45–48.
26. Hazin R, Ibrahim OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. *Ann Med*. 2008;40(2):hlm 129–138.
27. Chahal D, Aleshin M, Turegano M, Chiu M, Worswick S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. *Dermatol Online J*. 2018;24(1):hlm 1–10.
28. Wang L, Mei XL. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 88 Chinese patients. 2017;130(9):hlm 1062–1068.
29. Seth D, Kamat D. Drug Allergy. *Pediatr Ann*. 2018;47(10):hlm 419–25.
30. Holgate ST, Church MK, Broide DH, Martinez FD. Allergy. 2012. hlm 402.
31. Chung W-H, Hung S-I. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Allergol Int*. 2010;59(4):hlm 325–332.
32. Chung WH, Hung SI, Hong HS dkk. Medical genetics: a marker for stevens–johnson syndrome. *Nature*. 2004;428(6982):hlm 486.
33. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens–Johnson syndrome and toxic epidermal necrolysis: an update. *Am J Clin Dermatol*. 2015;16(6):hlm 475–493.
34. Chatproedprai S, Wutticharoenwong V, Tempark T, Wananukul S. Clinical features and treatment outcomes among children with Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year study in a tertiary referral hospital. *Dermatol Res Pract*. 2018.
35. Sato S, Kanbe T, Tamaki Z, Furuichi M, Uejima Y, Suganuma E, dk. Clinical features of Stevens–Johnson syndrome and toxic epidermal necrolysis. *Pediatr Int*. 2018;60(8):hlm 697–702.
36. Harr T, French LE. Toxic epidermal necrolysis in Stevens Johnson syndrome. *Orphanet J Rare Dis*. 2010;5(39):hlm 1–11.
37. Edell DS, Davidson JJ, Muelenaer AA, Majure M. Unusual manifestation of Stevens-Johnson syndrome involving the respiratory and gastrointestinal tract. *Pediatrics*. 1992;89(3):hlm 429–432.

38. Powell N. Colonic involvement in Stevens-Johnson syndrome. *Postgrad Med J.* 2006;82(10).
39. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. *Clin Rev Allergy Immunol.* 2017;hlm 1–30.
40. Fujita Y, Yoshioka N, Abe R, Murata J, Hoshina D, Mae H, dkk. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis. *J Am Acad Dermatol.* 2011;65(1):hlm 65–68.
41. Olteanu C, Shear NH, Chew HF, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, dkk. Severe physical complications among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. *Drug Saf.* 2018;41(3): hlm277–284.
42. Tchetnya X, Ngwasiri CA, Munge T, Aminde LN. Severe eye complications from toxic epidermal necrolysis following initiation of Nevirapine based HAART regimen in a child with HIV infection: a case from Cameroon. *BMC Pediatr.* 2018;18(1):hlm 1–6.
43. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, dkk. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. *Allergy Eur J Allergy Clin Immunol.* 2007;62(5):hlm 527–531.
44. Hung CC, Liu WC, Kuo MC, Lee CH, Hwang SJ, Chen HC. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Am J Nephrol.* 2009;29(6):hlm 633–638.
45. Cho YT, Chu CY. Treatments for severe cutaneous adverse reactions. *J Immunol Res.* 2017.
46. Papp A, Sikora S, Evans M, Song D, Kirchhof M, Miliszewski M, dkk. Treatment of toxic epidermal necrolysis by a multidisciplinary team: a review of literature and treatment results. *Burns.* 2018;44(4):hlm 807–815.
47. Ng QX, De Deyn MLZQ, Venkatanarayanan N, Ho CYX, Yeo WS. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. *J Inflamm Res.* 2018;11:hlm 135–142.
48. Weinand C, Xu W, Perbix W, Lefering R, Maegele M, Rathert M, dkk. 27 years of a single burn centre experience with Stevens – Johnson syndrome and toxic epidermal necrolysis: Analysis of mortality risk for causative agents. *BURNS.* 2013;hlm 1449-1455.
49. Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, dkk. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Am J Ophthalmol.* 2015;160(2):hlm 228–237.

50. Lalosevic J, Nikolic M, Gajic-Veljcic M, Skiljevic D, Medenica L. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. *Int J Dermatol.* 2015;54(8):hlm 978–984.
51. United Nations, Department of Economic and Social Affairs, Population Division. *World Population Prospects: The 2012 Revision, Highlights and Advance Tables.* Working Paper No. ESA/P/WP.228. 2013; hlm 106
52. Fatmah. Respons imunitas yang rendah pada tubuh manusia usia lanjut. 2006;10(1):hlm 47–53.
53. Shih KC, Wong IYH, Chan JCY, Lai JSM. A cross-sectional comparative study on chronic ocular manifestations of Stevens – Johnson syndrome and toxic epidermal necrolysis in Chinese eyes : a 15-year case series. *Int Ophthalmol.* 2017.

